ReviewJACC. Asia2025
Current Status of Tricuspid Valve Interventions in Asia Pacific Region.
Review in JACC. Asia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- Advancing the Evidence Base for Tricuspid TEER: Insights from the TEER-CHINA Trial.JACC. Asia · 2026Article
- Echocardiographic guidance in transcatheter tricuspid valve interventions.Journal of cardiovascular imaging · 2026Article
- Features and short-term outcomes of real-world transcatheter tricuspid valve repairAnnals of cardiothoracic surgery · 2026Article
- Initial Real-World Experience of Tricuspid Transcatheter Edge-to-Edge Repair in Asia.JACC. Asia · 2026Article
- Advancing Tricuspid Transcatheter Edge-to-Edge Repair in Asia: Insights From the Initial T-TEER Experience.JACC. Asia · 2026Article
- Another Engine to Advance the Development of Structural Heart Interventions: A Special Issue to Grow With the China Valve.JACC. Case reports · 2025Article
- Epidemiology of Valvular Heart Disease in Asia Pacific Region.JACC. Asia · 2025Review
- The Evolving Landscape of Tricuspid Regurgitation Management.JACC. Asia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcatheter tricuspid interventions are becoming increasingly more common in Asia Pacific. In the past decade, clinicians in Asia Pacific have worked with a multitude of new transcatheter tricuspid technologies. A standardized clinical algorithm to diagnose symptomatic tricuspid regurgitation to increase patient access to novel right heart therapies has not yet been identified. Anatomic diversity in the Asia Pacific patient population; disease prevalence patterns; and socioeconomic, cultural, and local health structures represent unique challenges in the treatment of these patients with right heart failure. As advancements are made in right heart failure and transcatheter tricuspid technologies, hopefully more patients can be treated not just in Asia Pacific, but across the entire world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.